-
A Beta-only IL-2 ImmunoTherapY Study
NCT05086692 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston
-
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
NCT05746897 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Dallas
-
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NCT06774963 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston, San Antonio
-
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
NCT07109726 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Austin, Houston, San Antonio
-
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT06695845 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Amarillo, Dallas, Houston, San Antonio
-
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NCT06586957 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Austin, Dallas
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT04657068 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Austin, Dallas, Flower Mound, Houston
-
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
NCT06778863 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Dallas, Houston
-
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
NCT06999187 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Austin, Dallas, San Antonio
-
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
NCT05377996 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Dallas, Houston
-
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston, San Antonio
-
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
NCT06943521 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston
-
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
NCT05877599 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston, Round Rock
-
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT06395519 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston
-
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
NCT04503265 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston
-
Comprehensive Outcomes for After Cancer Health
NCT05349227 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston
-
DESTINY-PANTUMOUR04
NCT07124000 ·
Phase: Not specified ·
Ages: 18 Years to 130 Years ·
Sex: All (male and female)
· Texas: Dallas
-
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
NCT07517198 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Fort Worth
-
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
NCT05983432 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston
-
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
NCT07216105 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston
-
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
NCT04038619 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston
-
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
NCT06303505 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Fort Worth, Irving
-
IDOV-Immune for Advanced Solid Tumors
NCT06910657 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston, San Antonio
-
Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.
NCT05649072 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: Female
· Texas: Houston
-
Lead-212 PSV359 Therapy for Patients With Solid Tumors
NCT06710756 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 90 Years ·
Sex: All (male and female)
· Texas: Houston
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
NCT06293898 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston
-
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
NCT05735080 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Dallas, Houston
-
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
NCT07424547 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Austin, San Antonio
-
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
NCT03452774 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· Texas: Dallas, Houston, Temple
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
NCT06582017 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: San Antonio
-
Sample Collection for Ongoing Research and Product Evaluation Study
NCT07318051 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Austin
-
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
NCT04981119 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston
-
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
NCT07444814 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Austin, Houston, San Antonio
-
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT05489211 ·
Phase: Phase 2 ·
Ages: 18 Years to 130 Years ·
Sex: All (male and female)
· Texas: Houston
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
NCT06545942 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: San Antonio
-
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
NCT07524322 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston, San Antonio
-
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
NCT05568680 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston
-
TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
NCT04969315 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston
-
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750 ·
Phase: Phase 1, Phase 2 ·
Ages: 12 Years and older ·
Sex: All (male and female)
· Texas: Austin, Bedford, Dallas, Houston
-
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
NCT05366881 ·
Phase: Not specified ·
Ages: 40 Years and older ·
Sex: All (male and female)
· Texas: Austin